uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy…
~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline and clinical benefits relative to…